Patents by Inventor Se-Woong Oh
Se-Woong Oh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240279203Abstract: The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.Type: ApplicationFiled: March 27, 2024Publication date: August 22, 2024Inventors: Sang Ho OH, Jong Gyun KIM, Se-Woong OH, Tae Dong HAN, Soo Yong CHUNG, Seong Ran LEE, Kyeong Bae KIM, Young Sung LEE, Woo Seob SHIN, Hyun JU, Jeong Ki KANG, Su Min PARK, Dong Kyun KIM
-
Patent number: 11981659Abstract: The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.Type: GrantFiled: March 17, 2022Date of Patent: May 14, 2024Assignee: Yuhan CorporationInventors: Sang Ho Oh, Jong Gyun Kim, Se-Woong Oh, Tae Dong Han, Soo Yong Chung, Seong Ran Lee, Kyeong Bae Kim, Young Sung Lee, Woo Seob Shin, Hyun Ju, Jeong Ki Kang, Su Min Park, Dong Kyun Kim
-
Publication number: 20230021395Abstract: The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.Type: ApplicationFiled: March 17, 2022Publication date: January 26, 2023Inventors: Sang Ho OH, Jong Gyun KIM, Se-Woong OH, Tae Dong HAN, Soo Yong CHUNG, Seong Ran LEE, Kyeong Bae KIM, Young Sung LEE, Woo Seob SHIN, Hyun JU, Jeong Ki KANG, Su Min PARK, Dong Kyun KIM
-
Patent number: 11490711Abstract: There is provided a cosmetic vessel. The cosmetic vessel includes an airless pump configured to discharge cosmetics accommodated therein by using a piston that rises in a cylinder, a discharge plate provided at one side of the airless pump and having at least one discharge hole, and a guide unit provided between the airless pump and the discharge plate. A lower end of the guide unit is combined with the piston and rises or falls in a state of being integrated with the piston.Type: GrantFiled: October 23, 2019Date of Patent: November 8, 2022Assignee: LG HOUSEHOLD & HEALTH CARE LTD.Inventors: Se Woong Oh, Ha Young Kim, Sung Hwan Kim, Sang Wook Park, Gu Yong Lee, Ji Mi Baek, Ok Hee Jung
-
Patent number: 11453656Abstract: The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yppyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.Type: GrantFiled: April 18, 2018Date of Patent: September 27, 2022Assignee: Yuhan CorporationInventors: Sang Ho Oh, Jong Gyun Kim, Se-Woong Oh, Tae Dong Han, Soo Yong Chung, Seong Ran Lee, Kyeong Bae Kim, Young Sung Lee, Woo Seob Shin, Hyun Ju, Jeong Ki Kang, Su Min Park, Dong Kyun Kim
-
Patent number: 11179440Abstract: A fusion protein containing a biologically active protein and an FGF21 mutant protein, a pharmaceutical composition containing the fusion protein, and their uses are disclosed. The fusion protein and the pharmaceutical composition are effective in treating a liver disease including hepatitis, hepatic fibrosis, and hepatic cirrhosis. The fusion protein has effects of inhibiting proliferation of inflammatory cells and fibroblasts, and thus can be effectively used for treating hepatitis, hepatic fibrosis, and hepatic cirrhosis.Type: GrantFiled: November 10, 2017Date of Patent: November 23, 2021Assignee: YUHAN CORPORATIONInventors: Han Na Hong, Jun Hwan Kim, Hyun Ho Choi, Dohoon Kim, Taewang Kim, Se Woong Oh, Moo Young Song, Jong Gyun Kim
-
Patent number: 11046742Abstract: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3? or CCL3? is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3? or CCL3? in the CCL3 variant.Type: GrantFiled: April 19, 2017Date of Patent: June 29, 2021Assignee: YUHAN CORPORATIONInventors: Su Youn Nam, Jong Gyun Kim, Byung Hyun Choi, June Hyung Lee, Ju Young Park, Jun Kyung Lee, Na Rae Lee, Ki Hong Kim, Seul Gi Kim, Se Woong Oh, Seung Yub Shin, Ho Woong Kang, Su Jin Ahn, Soo Yong Chung
-
Publication number: 20210139461Abstract: The present invention relates to novel mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yppyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, a novel crystalline form thereof, and a process for preparing the same. More specifically, the present invention relates to mesylate salt of N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide, which is excellent in stability, solubility, and bioavailability when it is administered not only alone but also in combination with other drugs and which has a high purity, a crystalline form thereof, and a process for preparing the same.Type: ApplicationFiled: April 18, 2018Publication date: May 13, 2021Inventors: Sang Ho OH, Jong Gyun KIM, Se-Woong OH, Tae Dong HAN, Soo Yong CHUNG, Seong Ran LEE, Kyeong Bae KIM, Young Sung LEE, Woo Seob SHIN, Hyun JU, Jeong Ki KANG, Su Min PARK, Dong Kyun KIM
-
Patent number: 10874191Abstract: The present disclosure relates to a cosmetic vessel. The cosmetic vessel includes a discharge unit discharging cosmetics to an outside, and a discharge plate provided at one side of the discharge unit from which the cosmetics are discharged, the discharge plate including a plurality of discharge holes, wherein the cosmetics are discharged through the plurality of discharge holes of the discharge plate, and a thin film is formed on one surface of the discharge plate exposed to the outside.Type: GrantFiled: June 1, 2018Date of Patent: December 29, 2020Assignee: LG HOUSEHOLD & HEALTH CARE LTD.Inventors: Se Woong Oh, Hyeon Jeong Kim, Hye Ryen Kim, Sang Wook Park, Jae Hong Jung, Kyungwon Kim, Ye Kyung Cho, Sung-Tae Kim, Guyong Lee, Sungsoo Kang, In Hwan Roh
-
Publication number: 20200054113Abstract: There is provided a cosmetic vessel. The cosmetic vessel includes an airless pump configured to discharge cosmetics accommodated therein by using a piston that rises in a cylinder, a discharge plate provided at one side of the airless pump and having at least one discharge hole, and a guide unit provided between the airless pump and the discharge plate. A lower end of the guide unit is combined with the piston and rises or falls in a state of being integrated with the piston.Type: ApplicationFiled: October 23, 2019Publication date: February 20, 2020Applicant: LG HOUSEHOLD & HEALTH CARE LTD.Inventors: Se Woong OH, Ha Young KIM, Sung Hwan KIM, Sang Wook PARK, Gu Yong LEE, Ji Mi BAEK, Ok Hee JUNG
-
Patent number: 10524558Abstract: There is provided a cosmetic vessel. The cosmetic vessel includes an airless pump configured to discharge cosmetics accommodated therein by using a piston that rises in a cylinder, a discharge plate provided at one side of the airless pump and having at least one discharge hole, and a guide unit provided between the airless pump and the discharge plate. A lower end of the guide unit is combined with the piston and rises or falls in a state of being integrated with the piston.Type: GrantFiled: August 8, 2016Date of Patent: January 7, 2020Assignee: LG HOUSEHOLD & HEALTH CARE LTD.Inventors: Se Woong Oh, Ha Young Kim, Sung Hwan Kim, Sang Wook Park, Gu Yong Lee, Ji Mi Baek, Ok Hee Jung
-
Publication number: 20190314452Abstract: The present invention provides a composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis. Specifically, the present invention provides a fusion protein comprising a biologically active protein and an FGF21 mutant protein; and a pharmaceutical composition containing the fusion protein, which is effective for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis. A pharmaceutical composition of the present invention has the effect of inhibiting proliferation of inflammatory cells and fibroblasts, and thus can be effectively used as a composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis.Type: ApplicationFiled: November 10, 2017Publication date: October 17, 2019Applicant: YUHAN CORPORATIONInventors: Han Na HONG, Jun Hwan KIM, Hyun Ho CHOI, Dohoon KIM, Taewang KIM, Se Woong OH, Moo Young SONG, Jong Gyun KIM
-
Patent number: 10426246Abstract: Provided herein is a cosmetic vessel including a discharge unit discharging cosmetics to an outside; and a discharge plate provided at one side of the discharge unit from which the cosmetics are discharged, including at least one discharge hole, wherein the discharge plate is provided with a discharge plate processed portion made of a material different from that of the discharge plate on at least a portion of at least one surface.Type: GrantFiled: February 3, 2015Date of Patent: October 1, 2019Assignee: LG HOUSEHOLD & HEALTH CARE LTD.Inventors: Se Woong Oh, Hyeon Jeong Kim, Hye Ryen Kim, Sang Wook Park, Jae Hong Jung, Kyungwon Kim, Ye Kyung Cho, Sung-Tae Kim, Guyong Lee, Sungsoo Kang, In Hwan Roh
-
Patent number: 10383859Abstract: The present invention provides a benzo[d]thiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzo[d]thiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the benzo[d]thiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.Type: GrantFiled: July 6, 2017Date of Patent: August 20, 2019Assignee: Yuhan CorporationInventors: Se-Woong Oh, Youn Hur, Jin-Hwi Park, Jae-Eun Joo, Ho-Woong Kang, Hyok-Jun Cho, Eui-Chul Lee, Chan-Sun Park, Dong-Hyun Kim, Jong-Gyun Kim, Su-Youn Nam
-
Publication number: 20190153055Abstract: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3? or CCL3? is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3? or CCL3? in the CCL3 variant.Type: ApplicationFiled: April 19, 2017Publication date: May 23, 2019Inventors: Su Youn Nam, Jong Gyun Kim, Byung Hyun Choi, June Hyung Lee, Ju Young Park, Jun Kyung Lee, Na Rae Lee, Ki Hong Kim, Seul Gi Kim, Se Woong Oh, Seung Yub Shin, Ho Woong Kang, Su Jin Ahn, Soo Yong Chung
-
Publication number: 20190142809Abstract: The present invention provides a benzo[d]thiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzo[d]thiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the benzo[d]thiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.Type: ApplicationFiled: July 6, 2017Publication date: May 16, 2019Applicant: Yuhan CorporationInventors: Se-Woong Oh, Youn Hur, Jin-Hwi Park, Jae-Eun Joo, Ho-Woong Kang, Hyok-Jun Cho, Eui-Chul Lee, Chan-Sun Park, Dong-Hyun Kim, Jong-Gyun Kim, Su-Youn Nam
-
Publication number: 20180279741Abstract: The present disclosure relates to a cosmetic vessel. The cosmetic vessel includes a discharge unit discharging cosmetics to an outside, and a discharge plate provided at one side of the discharge unit from which the cosmetics are discharged, the discharge plate including a plurality of discharge holes, wherein the cosmetics are discharged through the plurality of discharge holes of the discharge plate, and a thin film is formed on one surface of the discharge plate exposed to the outside.Type: ApplicationFiled: June 1, 2018Publication date: October 4, 2018Applicant: LG HOUSEHOLD & HEALTH CARE LTD.Inventors: Se Woong OH, Hyeon Jeong KIM, Hye Ryen KIM, Sang Wook PARK, Jae Hong JUNG, Kyungwon KIM, Ye Kyung CHO, Sung-Tae KIM, Guyong LEE, Sungsoo KANG, In Hwan ROH
-
Publication number: 20170354230Abstract: There is provided a cosmetic vessel. The cosmetic vessel includes an airless pump configured to discharge cosmetics accommodated therein by using a piston that rises in a cylinder, a discharge plate provided at one side of the airless pump and having at least one discharge hole, and a guide unit provided between the airless pump and the discharge plate. A lower end of the guide unit is combined with the piston and rises or falls in a state of being integrated with the piston.Type: ApplicationFiled: August 8, 2016Publication date: December 14, 2017Applicant: LG HOUSEHOLD & HEALTH CARE LTD.Inventors: Se Woong OH, Ha Young KIM, Sung Hwan KIM, Sang Wook PARK, Gu Yong LEE, Ji Mi BAEK, Ok Hee JUNG
-
Publication number: 20160242529Abstract: Provided herein is a cosmetic vessel including a discharge unit discharging cosmetics to an outside; and a discharge plate provided at one side of the discharge unit from which the cosmetics are discharged, including at least one discharge hole, wherein the discharge plate is provided with a discharge plate processed portion made of a material different from that of the discharge plate on at least a portion of at least one surface.Type: ApplicationFiled: February 3, 2015Publication date: August 25, 2016Applicant: LG HOUSEHOLD & HEALTH CARE LTD.Inventors: Se Woong OH, Hyeon Jeong KIM, Hye Ryen KIM, Sang Wook PARK, Jae Hong JUNG, Kyungwon KIM, Ye Kyung CHO, Sung-Tae KIM, Guyong LEE, Sungsoo KANG, In Hwan ROH
-
Patent number: 9070713Abstract: A power semiconductor device includes: a drain region of a first conductive type; a drift region of a first conductive type formed on the drain region; a first body region of a second conductive type formed below an upper surface of the drift region; a second body region of a second conductive type formed below the upper surface of the drift region and in the first body region; a third body region of a second conductive type formed by protruding downwards from a lower end of the first body region; a source region of a first conductive type formed below the upper surface of the drift region and in the first body region; and a gate insulating layer formed on channel regions of the first body region and on the drift region between the first body regions.Type: GrantFiled: January 27, 2014Date of Patent: June 30, 2015Assignee: Fairchild Korea Semiconductor Ltd.Inventors: Jin-myung Kim, Se-woong Oh, Jae-gil Lee, Young-chul Choi, Ho-cheol Jang